VQVu Minh Quan

Vu Minh Quan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vu Minh Quan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • David D. Celentano

    Johns Hopkins Bloomberg School of Public Health—Epidemiology, Baltimore, MD, USA

    3 shared publications
  • Carl Latkin

    From the Bloomberg School of Public Health (VMQ, CL, DDC), Johns Hopkins University, Baltimore, MD; Chiang Mai University (AA, TV, KW), Chiang Mai, Thailand; and Statistical Center for HIV/AIDS Research & Prevention (DD, T-YL), Seattle, WA

    2 shared publications
  • Tasanai Vongchak

    From the Bloomberg School of Public Health (VMQ, CL, DDC), Johns Hopkins University, Baltimore, MD; Chiang Mai University (AA, TV, KW), Chiang Mai, Thailand; and Statistical Center for HIV/AIDS Research & Prevention (DD, T-YL), Seattle, WA

    2 shared publications
  • Vivian F. Go

    Johns Hopkins Bloomberg School of Public Health—Epidemiology, Baltimore, MD, USA

    2 shared publications
  • A. Duerr

    Fred Hutchinson Cancer Research Center, HIV Vaccine Trials Network, Seattle, USA

    1 shared publication
  • A. W. Carrico

    Division of Prevention Science and Community Health, University of Miami, Miami, USA

    1 shared publication

Latest Publications

  • Open Access

    Individual and poly-substance use and condomless sex among HIV-uninfected adults reporting heterosexual sex in a multi-site cohort

    by R. J. Fredericksen, B. M. Whitney, E. Trejo, R. M. Nance, E. Fitzsimmons, F. L. Altice, A. W. Carrico, C. M. Cleland, C. Del Rio, A. Duerr, et al.

    Background: We analyzed the association between substance use (SU) and condomless sex (CS) among HIV-negative adults reporting heterosexual sex in the Seek, Test, Treat, and Retain (STTR) consortium. We describe the impact of SU as well as person/partner and context-related factors on CS, identifying combinations of factors that indicate the highest likelihood of CS. Methods: We analyzed data from four US-based STTR studies to examine the effect of SU on CS using two SU exposures: 1) recent SU (within 3 months) and 2) SU before/during sex. Behavioral data were collected via 1:1 or self-administered computerized interviews. Adjusted individual-study, multivariable relative risk regression was used to examine the relationship between CS and SU. We also examined interactions with type of sex and partner HIV status. Pooled effect estimates were calculated using traditional fixed-effects meta-analysis. We analyzed data for recent SU (n = 6781; 82% men, median age = 33 years) and SU before/during sex (n = 2915; 69% men, median age = 40 years). Results: For both exposure classifications, any SU other than cannabis increased the likelihood of CS relative to non-SU (8–16%, p-values< 0.001). In the recent SU group, however, polysubstance use did not increase the likelihood of CS compared to single-substance use. Cannabis use did not increase the likelihood of CS, regardless of frequency of use. Type of sex was associated with CS; those reporting vaginal and anal sex had a higher likelihood of CS compared to vaginal sex only for both exposure classifications (18–21%, p < 0.001). Recent SU increased likelihood of CS among those reporting vaginal sex only (9–10%, p < 0.001); results were similar for those reporting vaginal and anal sex (5–8%, p < 0.01). SU before/during sex increased the likelihood of CS among those reporting vaginal sex only (20%; p < 0.001) and among those reporting vaginal and anal sex (7%; p = 0.002). Single- and poly-SU before/during sex increased the likelihood of CS for those with exclusively HIV-negative partners (7–8%, p ≀ 0.02), and for those reporting HIV-negative and HIV-status unknown partners (9–13%, p ≀ 0.03). Conclusion: Except for cannabis, any SU increased the likelihood of CS. CS was associated with having perceived HIV-negative partners and with having had both anal/vaginal sex.


  • Mortality Among Injection Drug Users in Northern Thailand: A Prospective Cohort Study

    by Vu Minh Quan, Apinun Aramrattana, Tasanai Vongchak, Carl Latkin, Deborah Donnell, Ting-Yuan Msc Liu, Kanokporn Bsc Wiboonnatakul, David D. Dsc Celentano

    Objectives: To measure mortality rates and assess predictors of all-cause mortality in a cohort of Thai injection drug users (IDUs) who were enrolled and followed up from 2004 through 2006. Methods: In this prospective cohort study, we enrolled 314 community-dwelling IDUs (95% being men; 42% of ethnic minority; median age, 29 years [range, 18–69 years]) and followed up them at 6-month intervals. Mortality rates were calculated based on person-years of follow-up. Marginal Cox proportional hazards models for clustered data were constructed to determine the factors associated with all-cause mortality. Findings: During 445.7 person-years of follow-up, 17 of 314 (5.4%) IDUs died. The all-cause mortality rate was 3.8 per 100 person-years (95% confidence interval [CI] = 2.2–6.1). The standardized mortality ratio was 5.8 (95% CI = 3.5–9.1). The mortality rate among HIV-positive IDUs was 13.4 per 100 person-years (95% CI = 5.4–27.6). In a marginal Cox proportional-hazards model for clustered data, the excess mortality was associated with HIV-positivity (hazard ratio [HR] = 7.0, 95% CI = 2.8–17.6), benzodiazepine use (HR = 3.1, 95% CI = 1.1–9.4), and excessive alcohol consumption at enrollment (HR = 3.5, 95% CI = 1.3–9.1). Conclusions: The all-cause mortality among the drug injectors is high. The increased mortality was associated with HIV infection, benzodiazepine use, and excessive alcohol consumption.


  • Mortality and HIV transmission among male Vietnamese injection drug users

    by Vu Minh Quan, Nguyen Le Minh, Tran Viet Ha, Nguyen Phuong Ngoc, Pham The Vu, David D. Celentano, Tran Thi Mo, Vivian F. Go

    Aims  To estimate all‐cause mortality rate and to assess predictors of all‐cause mortality among injection drug users (IDUs) in Thai Nguyen province, Vietnam between 2005 and 2007.Design  Prospective cohort study.Setting  Community‐dwelling IDUs were enrolled and followed at 3‐month intervals for up to 2 years.Participants  A total of 894 male IDUs (median age of 32 years, 22.8% HIV‐positive, all having injected opioids).Measurements   Deaths were confirmed by family members and by reviewing government records. Marginal Cox proportional hazards models for clustered data were constructed to determine the independent predictors of all‐cause mortality, using both fixed baseline measurements and time‐dependent repeated measurements.Findings  During 710.1 person‐years of follow‐up, 45 (5.0%) drug injectors died. The causes of deaths were AIDS‐related (14 cases, 31%), drug overdose (12, 27%), suicide (three, 7%), traffic accident (three, 7%), violence (two, 4%), pneumonia (two, 4%), non‐traffic accident (one, 2%) and unknown causes (eight, 18%). The all‐cause mortality rate was 6.3% (95% CI = 4.6–8.5) per 100 person‐years. The standardized mortality ratio was 13.4. The HIV incidence rate was 5.2 (95% CI = 3.5–7.6) per 100 person‐years. In multi‐factorial analysis, HIV infection [hazard ratio (HR) = 3.5, 95% CI = 1.9–6.3] and previous diagnosis of tuberculosis (HR = 10.0, 95% CI = 4.1–24.3) were associated significantly with increased hazard of death.Conclusions  The all‐cause, age‐ and sex‐standardized mortality among Vietnamese IDUs is 13‐fold higher than the general population and substantially higher than IDUs studied in developed countries. Effective prevention and control of HIV infection and tuberculosis are needed urgently.


  • Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case–control study

    by Vu Minh Quan, Vivian F. Go, Le Van Nam, Anna Bergenstrom, Nguyen Phuong Thuoc, Jonathan Zenilman, Carl Latkin, David D. Celentano

    Injection drug use (IDU) and HIV infection are important public health problems in Vietnam. The IDU population increased 70% from 2000 to 2004 and is disproportionately affected by HIV and AIDS -- the country's second leading cause of death. Hepatitis B virus (HBV) and hepatitis C virus (HCV) share transmission routes with HIV and cause serious medical consequences. This study aimed to determine risk factors for acquisition of HIV, HBV, and HCV infections among IDUs in a northern province. We conducted a matched case-control study among active IDUs aged 18-45 who participated in a community-based survey (30-minute interview and serologic testing). Each HIV-infected IDU (case) was matched with one HIV-uninfected IDU (control) by age, sex (males only), and study site (128 pairs). Similar procedures were used for HBV infection (50 pairs) and HCV infection (65 pairs). Conditional logistic regression models were fit to identify risk factors for each infection. Among 309 surveyed IDUs, the HIV, HBV, and HCV prevalence was 42.4%, 80.9%, and 74.1%, respectively. Only 11.0% reported having been vaccinated against hepatitis B. While 13.3% of the IDUs reported sharing needles (past six months), 63.8% engaged in indirect sharing practices (past six months), including sharing drug solutions, containers, rinse water, and frontloading drugs. In multivariable models, sharing drugs through frontloading was significantly associated with HIV infection (odds ratio [OR]=2.8), HBV infection (OR=3.8), and HCV infection (OR=4.6). We report an unrecognized association between sharing drugs through frontloading and higher rates of HIV, HBV and HCV infections among male IDUs in Vietnam. This finding may have important implications for bloodborne viral prevention for IDUs in Vietnam.


  • Predictors of mortality among injecting and non‐injecting HIV‐negative drug users in northern Thailand

    by Vu Minh Quan, Tasanai Vongchak, Jaroon Jittiwutikarn, Surinda Kawichai, Namtip Srirak, Kanokporn Wiboonnatakul, Myat Htoo Razak, Vinai Suriyanon, David D. Celentano

    Aims  To estimate mortality rates among HIV‐negative injecting drug users (IDUs) and non‐injecting drug users (non‐IDUs), and to assess predictors for mortality among the IDUs.Design  Prospective cohort study in northern Thailand with 2‐year follow‐up.Setting  IDUs and non‐IDUs who were admitted for detoxification treatment for opiate or amphetamine dependence in a regional drug treatment center were screened. After discharge, HIV‐negative individuals were followed‐up in the community.Participants  A total of 821 HIV‐negative drug users [346 IDUs (42%) and 475 non‐IDUs, median age = 32; 51% were ethnic minorities].Measurements  All‐cause mortality.Findings  There were 33 deaths over 1360 person‐years of follow‐up. The all‐cause mortality rate was 39 per 1000 person‐years among IDUs [standardized mortality ratio (SMR) = 13.9], and was 14 per 1000 person‐years among non‐IDUs (SMR = 4.4). Among male IDUs, the hazards for all‐cause deaths were ethnic minority status [adjusted hazard ratio (HR) = 2.9, 95% CI = 1.2–7.2], incident HIV infection (HR = 2.8, 95% CI = 1.1–7.7) and longer duration of drug injection (HR = 1.07, 95% CI = 1.01–1.14).Conclusions  The mortality among IDUs is high. Being from an ethnic minority, recent HIV acquisition, and a greater number of years of drug injection are predictors of mortality among the IDUs in this region.